Ugandan biotech entrepreneur Dr. Matthias Magoola has been recognized as one of Africa's 100 most influential people, highlighting his role in advancing regional healthcare and reducing reliance on imported medicines. The honor, awarded at a ceremony in Kigali on Friday, celebrates his leadership in biotechnology and contributions to economic development, according to organizers of the 100 Africa Most Influential Persons Awards. The event, now in its third year, brought together leaders from across the continent working in sectors ranging from healthcare to community development.
Dr. Magoola, founder of Dei BioPharma, was acknowledged for his efforts to establish Africa's largest vaccine and medicine manufacturing complex. His company, which has submitted 65 product applications to Uganda's National Drug Authority, has secured approval for 40 products to manufacture and 14 to sell. The firm's 250-acre campus in Matugga, Wakiso District, is set to house 30 factories, aiming to bolster the continent's self-sufficiency in health products. This aligns with the African Union's 2040 target of producing 60% of its medicines locally, a goal underscored by the pandemic's exposure of supply chain vulnerabilities.
The awards, organized by the Business Executive Media Group and the International Business Council Africa, were judged by a 12-member panel evaluating candidates' impact on socio-economic development. Dr. Baroness Paulette Kporo, chair of Business Executive Media Group, emphasized the importance of recognizing individuals shaping Africa's trajectory. University of Rwanda Vice-Chancellor Prof Didas Muganga Kayihura, who presided over the ceremony, called for greater innovation to strengthen regional economies. 'As Africa integrates into the global economy, we must honor those driving progress in communities, sectors, and geographies,' he stated.
Dr. Magoola credited Ugandan President Yoweri Museveni for his support, calling the recognition a testament to national leadership. 'These achievements belong to Uganda, and specifically to our president, who has always stood by the scientists of this country,' he said. The honor follows recent milestones, including Dei BioPharma's registration under the African Pooled Procurement Mechanism on 1 September, granting the firm access to continental supply contracts. This shift marks the company's transition from infrastructure development to producing regulated medicines for broader markets.
The firm's research spans affordable cancer treatments, mRNA-based vaccines, and therapies for diseases like HIV, malaria, and sickle cell anemia. Dr. Magoola has filed over 100 patent applications with the US Patent and Trademark Office, including seven for mRNA cancer vaccines targeting recurring genetic mutations. A published application for a foot-and-mouth disease vaccine could save Uganda billions in import costs. His work has also earned international acclaim, including the 2025 Ratna Pharma Award in India and the 2024 International Molecular Biologist Awards for mRNA drug research.
Dei BioPharma's expansion reflects growing regional investment in biotechnology. The company's focus on training African researchers and developing locally adapted solutions positions it as a key player in the continent's health sector. With its Kigali recognition, Dr. Magoola joins a network of leaders driving Africa's socio-economic transformation. 'Our vision is to ensure that African nations lead in healthcare innovation,' he said, underscoring the importance of sustained public and private collaboration.
The awards ceremony highlighted the intersection of science, policy, and economic development, with participants emphasizing the need for systemic change. As Africa seeks to reduce dependency on foreign pharmaceuticals, initiatives like Dei BioPharma's represent a critical step toward self-reliance. Dr. Magoola's recognition underscores the growing influence of African innovators in shaping the continent's future.
The 100 Africa Most Influential Persons Awards, which celebrated leaders across industries, also featured Ugandan representatives in education, technology, and community advocacy. The event served as a platform for dialogue on Africa's development challenges and opportunities. Organizers noted that the selection process prioritized candidates whose work addresses pressing regional needs, from healthcare access to economic empowerment.
Dr. Magoola's journey from academic research to biotech entrepreneurship illustrates the potential of African-led innovation. His company's progress, including the recent African Pooled Procurement Mechanism registration, signals a shift toward sustainable healthcare solutions. As the continent strives for greater autonomy in medicine production, his work remains a focal point for policymakers and investors alike.
The recognition in Kigali adds to Dr. Magoola's growing list of accolades, reflecting the global attention on African scientific advancements. With ongoing projects targeting both public health and commercial markets, Dei BioPharma continues to position itself as a leader in the region's biotech landscape. The firm's success highlights the importance of supportive policies and infrastructure in fostering innovation across Africa.
The broader implications of Dr. Magoola's work extend beyond Uganda, offering a model for other nations seeking to build resilient healthcare systems. As the African Union sets ambitious production targets, the role of private enterprises like Dei BioPharma becomes increasingly vital. Their efforts not only address immediate health needs but also contribute to long-term economic growth and regional stability.